U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Increased risk of myelodysplastic syndromes

MedGen UID:
413242
•Concept ID:
C2750177
•
Finding
Synonym: Increased risk for myelodysplastic syndrome

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVIncreased risk of myelodysplastic syndromes

Professional guidelines

PubMed

Risk of myelodysplastic syndrome and acute myeloid leukemia post radiation treatment for breast cancer: a population-based study.
Kaplan H, Malmgren J, De Roos AJ
Breast Cancer Res Treat 2013 Feb;137(3):863-7. Epub 2012 Dec 30 doi: 10.1007/s10549-012-2386-9. PMID: 23274844

Recent clinical studies

Etiology

Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol 2023 Aug;98(8):1307-1325. Epub 2023 Jun 8 doi: 10.1002/ajh.26984. PMID: 37288607
Epidemiology and Pathogenesis of Myelodysplastic Syndrome.
Rotter LK, Shimony S, Ling K, Chen E, Shallis RM, Zeidan AM, Stahl M
Cancer J 2023 May-Jun 01;29(3):111-121. doi: 10.1097/PPO.0000000000000665. PMID: 37195766
Myelodysplastic syndromes.
Li H, Hu F, Gale RP, Sekeres MA, Liang Y
Nat Rev Dis Primers 2022 Nov 17;8(1):74. doi: 10.1038/s41572-022-00402-5. PMID: 36396662
Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.
Sekeres MA, Taylor J
JAMA 2022 Sep 6;328(9):872-880. doi: 10.1001/jama.2022.14578. PMID: 36066514
Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.
Garcia-Manero G, Chien KS, Montalban-Bravo G
Am J Hematol 2020 Nov;95(11):1399-1420. doi: 10.1002/ajh.25950. PMID: 32744763

Diagnosis

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
Platzbecker U, Della Porta MG, Santini V, Zeidan AM, Komrokji RS, Shortt J, Valcarcel D, Jonasova A, Dimicoli-Salazar S, Tiong IS, Lin CC, Li J, Zhang J, Giuseppi AC, Kreitz S, Pozharskaya V, Keeperman KL, Rose S, Shetty JK, Hayati S, Vodala S, Prebet T, Degulys A, Paolini S, Cluzeau T, Fenaux P, Garcia-Manero G
Lancet 2023 Jul 29;402(10399):373-385. Epub 2023 Jun 10 doi: 10.1016/S0140-6736(23)00874-7. PMID: 37311468
Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol 2023 Aug;98(8):1307-1325. Epub 2023 Jun 8 doi: 10.1002/ajh.26984. PMID: 37288607
Myelodysplastic syndromes.
Li H, Hu F, Gale RP, Sekeres MA, Liang Y
Nat Rev Dis Primers 2022 Nov 17;8(1):74. doi: 10.1038/s41572-022-00402-5. PMID: 36396662
Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.
Sekeres MA, Taylor J
JAMA 2022 Sep 6;328(9):872-880. doi: 10.1001/jama.2022.14578. PMID: 36066514
Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.
Garcia-Manero G, Chien KS, Montalban-Bravo G
Am J Hematol 2020 Nov;95(11):1399-1420. doi: 10.1002/ajh.25950. PMID: 32744763

Therapy

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
Platzbecker U, Della Porta MG, Santini V, Zeidan AM, Komrokji RS, Shortt J, Valcarcel D, Jonasova A, Dimicoli-Salazar S, Tiong IS, Lin CC, Li J, Zhang J, Giuseppi AC, Kreitz S, Pozharskaya V, Keeperman KL, Rose S, Shetty JK, Hayati S, Vodala S, Prebet T, Degulys A, Paolini S, Cluzeau T, Fenaux P, Garcia-Manero G
Lancet 2023 Jul 29;402(10399):373-385. Epub 2023 Jun 10 doi: 10.1016/S0140-6736(23)00874-7. PMID: 37311468
Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol 2023 Aug;98(8):1307-1325. Epub 2023 Jun 8 doi: 10.1002/ajh.26984. PMID: 37288607
Myelodysplastic syndromes.
Li H, Hu F, Gale RP, Sekeres MA, Liang Y
Nat Rev Dis Primers 2022 Nov 17;8(1):74. doi: 10.1038/s41572-022-00402-5. PMID: 36396662
Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.
Sekeres MA, Taylor J
JAMA 2022 Sep 6;328(9):872-880. doi: 10.1001/jama.2022.14578. PMID: 36066514
Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.
Garcia-Manero G, Chien KS, Montalban-Bravo G
Am J Hematol 2020 Nov;95(11):1399-1420. doi: 10.1002/ajh.25950. PMID: 32744763

Prognosis

Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol 2023 Aug;98(8):1307-1325. Epub 2023 Jun 8 doi: 10.1002/ajh.26984. PMID: 37288607
Myelodysplastic syndromes.
Li H, Hu F, Gale RP, Sekeres MA, Liang Y
Nat Rev Dis Primers 2022 Nov 17;8(1):74. doi: 10.1038/s41572-022-00402-5. PMID: 36396662
Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.
Sekeres MA, Taylor J
JAMA 2022 Sep 6;328(9):872-880. doi: 10.1001/jama.2022.14578. PMID: 36066514
The Genetics of Myelodysplastic Syndromes: Clinical Relevance.
Chiereghin C, Travaglino E, Zampini M, Saba E, Saitta C, Riva E, Bersanelli M, Della Porta MG
Genes (Basel) 2021 Jul 27;12(8) doi: 10.3390/genes12081144. PMID: 34440317Free PMC Article
Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.
Garcia-Manero G, Chien KS, Montalban-Bravo G
Am J Hematol 2020 Nov;95(11):1399-1420. doi: 10.1002/ajh.25950. PMID: 32744763

Clinical prediction guides

Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial.
Platzbecker U, Della Porta MG, Santini V, Zeidan AM, Komrokji RS, Shortt J, Valcarcel D, Jonasova A, Dimicoli-Salazar S, Tiong IS, Lin CC, Li J, Zhang J, Giuseppi AC, Kreitz S, Pozharskaya V, Keeperman KL, Rose S, Shetty JK, Hayati S, Vodala S, Prebet T, Degulys A, Paolini S, Cluzeau T, Fenaux P, Garcia-Manero G
Lancet 2023 Jul 29;402(10399):373-385. Epub 2023 Jun 10 doi: 10.1016/S0140-6736(23)00874-7. PMID: 37311468
Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol 2023 Aug;98(8):1307-1325. Epub 2023 Jun 8 doi: 10.1002/ajh.26984. PMID: 37288607
Myelodysplastic syndromes.
Li H, Hu F, Gale RP, Sekeres MA, Liang Y
Nat Rev Dis Primers 2022 Nov 17;8(1):74. doi: 10.1038/s41572-022-00402-5. PMID: 36396662
Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.
Sekeres MA, Taylor J
JAMA 2022 Sep 6;328(9):872-880. doi: 10.1001/jama.2022.14578. PMID: 36066514
Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.
Garcia-Manero G, Chien KS, Montalban-Bravo G
Am J Hematol 2020 Nov;95(11):1399-1420. doi: 10.1002/ajh.25950. PMID: 32744763

Recent systematic reviews

The efficacy and adverse events of arsenic trioxide for the patients with myelodysplastic syndrome: a systematic review and component network meta-analysis.
Huang X, Liu Y, Liu R, Zou X, Yang H
Hematology 2023 Dec;28(1):2274149. Epub 2023 Oct 31 doi: 10.1080/16078454.2023.2274149. PMID: 37908176
Incidence and risk of hematologic toxicities with hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukopenia: A systematic review and meta-analysis.
Gao C, Wang J, Li Y, Zhao H, Li R, Hou L, Zhang Y, Tian S, Liang H, Wang C, Chen X, Wang J
Medicine (Baltimore) 2018 Aug;97(34):e11860. doi: 10.1097/MD.0000000000011860. PMID: 30142779Free PMC Article
Safety and efficacy of thrombopoietin-receptor agonists in myelodysplastic syndromes: a systematic review and meta-analysis of randomized controlled trials.
Prica A, Sholzberg M, Buckstein R
Br J Haematol 2014 Dec;167(5):626-38. Epub 2014 Aug 26 doi: 10.1111/bjh.13088. PMID: 25155450
Risk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and meta-analysis.
Nardone B, Wu S, Garden BC, West DP, Reich LM, Lacouture ME
Clin Lymphoma Myeloma Leuk 2013 Aug;13(4):424-9. Epub 2013 Jun 13 doi: 10.1016/j.clml.2013.03.006. PMID: 23769670
GSTT1 and GSTM1 polymorphisms and myelodysplastic syndrome risk: a systematic review and meta-analysis.
Dahabreh IJ, Giannouli S, Gota V, Voulgarelis M
Int J Cancer 2010 Apr 1;126(7):1716-23. doi: 10.1002/ijc.24940. PMID: 19816935

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...